Introduction: Gastric cancer is a global public health problem and the fifth most common type of neoplasm worldwide and is associated with high mortality rates, attributed not only to late diagnosis but also to the inefficacy of current treatments, highlighting the urgent need for research into new therapeutic approaches. From this perspective, geopropolis, a mixture of propolis (a combination of resins, plant exudates, and enzymes secreted by bees) with clay or soil, has emerged as a promising research target due to its strong antioxidant, antibacterial, and antineoplastic potential, considering its composition, which is rich in phenolic compounds and flavonoids. Objective: In light of this scenario, this study aimed to analyze the possible cytotoxic effects of three different types of geopropolis extracts in an in vitro gastric cancer model. Methods: For this purpose, metastatic gastric cancer cells (AGP01) and non-neoplastic human embryonic kidney cells (HEK-293) were subjected to the MTT cell viability assay to evaluate the cytotoxic potential of three geopropolis extracts obtained from the bee species Melipona flavolineata (UA), Melipona seminigra pernigra (UBR), and Melipona fasciculata (UC). The cell cultures were treated with concentrations of 200, 100, 50, 25, 12.5, 6.25 and 3.125 ?g/mL for 72 hours. The data were analyzed using nonlinear regression, applying a dose-response sigmoid equation to determine the mean inhibitory concentration (IC50), using GraphPad Prism v9 software. The statistical comparison between groups was conducted using one-way ANOVA, followed by the Bonferroni correction, with significance level set at p<0.05. Additionally, selectivity indexes (IS) were calculated for each treatment, allowing for a comparative analysis of the effects on tumor and non-tumor cells. Results: Our results showed that the extract obtained from the UBR species had an IC50 value of 8.3 ?g/mL for AGP01 and of 22.2 ?g/mL for HEK-293. For geopropolis from the UC species, the IC50 value exceeded 200 ?g/mL for AGP01 and was 54.08 ?g/mL for HEK-293. As for geopropolis from the UA species, it presented a IC50 value greater than 200 ?g/mL for AGP01 and was 27.05 ?g/mL for HEK-293. Regarding the selectivity indexes, no selectivity was observed for treatments with geopropolis from the UC and UA species, however, the one from the UBR species demonstrated high selectivity (IS=2.7). Conclusion: In summary, given the high selective cytotoxic potential shown by the geopropolis extract produced by the species Melipona seminigra pernigra in a metastatic gastric cancer cell model, it is suggested that this compound can be a promising candidate for the development of more effective and selective antineoplastic therapies. Its differential effect on tumor cells compared with non-tumor cells reinforces its therapeutic potential, especially in advanced stages of the disease, where safer and more precise alternatives are urgently needed.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
